April 19 (Reuters) - GW Pharmaceuticals Plc's cannabis-based drug to treat a severe form of childhood epilepsy was unanimously backed on Thursday by an advisory panel to the U.S. Food and Drug Administration. The positive vote sets the stage for the approval of the first-ever cannabis-derived ...
read more here
Delivered by @can_nab_is
No comments:
Post a Comment